tiprankstipranks
Trending News
More News >
SAB Biotherapeutics (SABS)
NASDAQ:SABS
US Market

SAB Biotherapeutics (SABS) Income Statement

Compare
315 Followers

SAB Biotherapeutics Income Statement

Last quarter (Q4 2025), SAB Biotherapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, SAB Biotherapeutics's net income was $-16.86M. See SAB Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Mar 25Dec 23Mar 23Dec 21
Total Revenue
$ 0.00$ 1.32M$ 2.24M$ 23.90M$ 60.88M
Gross Profit
$ -3.08M$ -3.47M$ -1.51M$ 20.61M$ 59.22M
Operating Expenses
$ 45.87M$ 39.44M$ 36.57M$ 49.53M$ 72.62M
Depreciation and Amortization
$ 3.08M$ 4.79M$ 3.75M$ 3.29M$ 1.65M
EBITDA
$ -45.87M$ -28.99M$ -38.13M$ -15.12M$ -15.20M
Operating Income
$ -48.95M$ -42.91M$ -38.08M$ -28.92M$ -13.39M
Other Income/Expenses
$ 62.23M$ 8.81M$ -4.12M$ 10.20M$ -3.75M
Pretax Income
$ 13.27M$ -34.11M$ -42.19M$ -18.72M$ -17.14M
Net Income
$ 13.27M$ -34.11M$ -42.19M$ -18.74M$ -17.14M
Per Share Metrics
Basic EPS
$ 0.22$ -3.68$ -7.64$ -4.31$ -3.94
Diluted EPS
$ -0.79$ -3.68$ -7.64$ -4.31$ -6.30
Weighted Average Shares Outstanding
19.31M 9.26M 5.52M 4.35M 4.35M
Weighted Average Shares Outstanding (Diluted)
61.34M 9.26M 5.52M 4.35M 2.73M
Currency in USD

SAB Biotherapeutics Earnings and Revenue History